Who owns secukinumab?

Who owns secukinumab today?

Secukinumab (brand name Cosentyx) is owned and marketed by Novartis. It is a drug developed by Novartis and remains under Novartis’ commercial control.[1]

Who originally developed secukinumab?

Novartis is also the original developer of secukinumab, which is why Novartis is listed as the company associated with the medicine in drug and patent tracking resources.[1]

Does any other company “own” secukinumab in some markets?

Typically, “ownership” of a drug like secukinumab is tied to the originator company that holds the key marketing and intellectual-property rights. For secukinumab, Novartis is the originator/owner referenced in the available sources; other firms may market versions or biosimilars, but those are separate products with their own approvals and rights rather than ownership of the original product.[1]

Where can I verify the company tied to secukinumab?

You can cross-check the company associated with secukinumab (including rights/patent context) via DrugPatentWatch: https://www.drugpatentwatch.com/p/secukinumab/.[1]

Sources:
[1] https://www.drugpatentwatch.com/p/secukinumab/